FILE ON PUBLIC HEALTH AGENCY OF CANADACompany

Public Health Agency of Canada

The agency relied on two internal drug-report searches in May and July 2001 that found no adverse drug reports involving OxyContin.1. The 2006 revision merely added the word "usually" to the misleading claim — i.e., "Drug abuse is usually not a problem…"2.

5 SOURCES · 8 DOCUMENTED FACTS · 5 DISPUTED · OPENED 2026-07-24 · UPDATED 2026-07-24
On the record see profile →

The agency relied on two internal drug-report searches in May and July 2001 that found no adverse drug reports involving OxyContin.

The Fentanyl Crisis Research Synthesis: Sharpest Evidence fo
“The agency relied on two internal drug-report searches in May and July 2001 that "found no adverse drug reports involving OxyContin."”
VERIFIED — a word-for-word match in the stored source

The 2006 revision merely added the word "usually" to the misleading claim — i.e., "Drug abuse is usually not a problem…"

The Fentanyl Crisis Research Synthesis: Sharpest Evidence fo
“The 2006 revision merely added the word "**usually**" to the misleading claim — i.e., "Drug abuse is *usually* not a problem…"”
VERIFIED — a word-for-word match in the stored source

Health Canada was aware of the FDA action and treats the FDA as a reliable source of information for monitoring drugs for safety problems, specifically with regard to prescription drug abuse.

The Fentanyl Crisis Research Synthesis: Sharpest Evidence fo
“Health Canada was aware of the FDA action and "treats the FDA as a reliable source of information for monitoring drugs for safety problems, specifically with regard to prescription drug abuse."”
VERIFIED — a word-for-word match in the stored source

Valerian Labs was Health Canada-licensed to manufacture natural health products

Health Canada began collecting user fees from pharmaceutical companies in 1994

The Fentanyl Crisis Research Synthesis: Sharpest Evidence fo
“Critics often point to **1994** as a turning point... That was the year when Health Canada began collecting **user fees from pharmaceutical companies** for performing various regulatory activities, including reviewing new drug applications.”
VERIFIED — a word-for-word match in the stored source

Xylazine first appeared in Health Canada DAS samples in 2018

How We Got Here: A Field Guide to the Fentanyl Crisis in Can
“first appeared in Health Canada DAS samples in 2018”
VERIFIED — a word-for-word match in the stored source

OxyContin was approved by Health Canada in 1996

How We Got Here: A Field Guide to the Fentanyl Crisis in Can
“OxyContin — Purdue Pharma's controlled-release oxycodone — was approved by Health Canada in 1996”
VERIFIED — a word-for-word match in the stored source

expanded naloxone distribution as the single most likely factor in the modest 2024 mortality decline

How We Got Here: A Field Guide to the Fentanyl Crisis in Can
“Public Health Agency of Canada's December 2025 analysis”
VERIFIED — a word-for-word match in the stored source
Disputed — who says what, against what see standalone →

These are things people say about Public Health Agency of Canada that aren't settled fact — each one attributed to who's actually claiming it, so a claim never quietly passes as established just because it showed up in a document. Weigh it yourself.

Disputed
"the regulatory delay was a material contributor to the Canadian over-prescription epidemic"
Asserted by Bavli · stance: pro
The evidence on file mostly supports this, but it's still someone's claim, not a settled fact.
How We Got Here: A Field Guide to the Fentanyl Crisis in Can ↗
Disputed
"the naloxone-only response is inadequate for the new pharmacology"
Asserted by Dr. Peter Wu · stance: pro
Not yet independently weighed — one source's claim, unconfirmed elsewhere.
The Fentanyl Crisis Research Synthesis: Sharpest Evidence fo ↗
Disputed
"the appearance of these wounds among the visibly homeless population has accelerated through 2023–2026"
Asserted by Public Health Agency of Canada · stance: pro
Not yet independently weighed — one source's claim, unconfirmed elsewhere.
How We Got Here: A Field Guide to the Fentanyl Crisis in Can ↗
Disputed
"Health Canada's delayed response allowed Purdue to use the misleading information in its promotional materials for more than 10 years (1996–2006)."
Asserted by Itai Bavli · stance: critical
The evidence on file mostly supports this, but it's still someone's claim, not a settled fact.
The Fentanyl Crisis Research Synthesis: Sharpest Evidence fo ↗
Disputed
"Health Canada's role in precipitating the overdose crisis has not received greater scrutiny"
Asserted by Jessie Pappin · stance: critical
Not yet independently weighed — one source's claim, unconfirmed elsewhere.
The Fentanyl Crisis Research Synthesis: Sharpest Evidence fo ↗
1994
1994
introduction of user fees
1996
1996
approval of OxyContin
1996
OxyContin approval
2001
2001–2006
Regulatory delay
2006
2006
Health Canada revised the drug's monograph
2022
2022
publication of Pappin/Bavli/Herder paper
2024
2024
Naloxone distribution
May 2024
BC asked Health Canada to amend exemption
Undated
Canadian fentanyl crisis
People